scholarly journals Vaccination with Combination DNA and Virus-Like Particles Enhances Humoral and Cellular Immune Responses upon Boost with Recombinant Modified Vaccinia Virus Ankara Expressing Human Immunodeficiency Virus Envelope Proteins

Vaccines ◽  
2017 ◽  
Vol 5 (4) ◽  
pp. 52 ◽  
Author(s):  
Sailaja Gangadhara ◽  
Young-Man Kwon ◽  
Subbiah Jeeva ◽  
Fu-Shi Quan ◽  
Baozhong Wang ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Immune Responses ◽  
Vaccinia Virus ◽  
Envelope Proteins ◽  
Virus Envelope ◽  
Cellular Immune Responses ◽  
Human Immunodeficiency Virus Envelope ◽  
Modified Vaccinia Virus Ankara ◽  
Immunodeficiency Virus ◽  
Cellular Immune

scholarly journals Attenuated Modified Vaccinia Virus Ankara Can Be Used as an Immunizing Agent under Conditions of Preexisting Immunity to the Vector

2000 ◽  
Vol 74 (16) ◽  
pp. 7651-7655 ◽  
Author(s):  
Juan C. Ramírez ◽  
M. Magdalena Gherardi ◽  
Dolores Rodríguez ◽  
Mariano Esteban
Keyword(s):  
Human Immunodeficiency Virus ◽  
Immune Responses ◽  
Vaccinia Virus ◽  
Human Immunodeficiency Virus Type ◽  
Human Population ◽  
Cellular Immune Responses ◽  
Modified Vaccinia Virus Ankara ◽  
Immunodeficiency Virus ◽  
Cellular Immune

ABSTRACT A problem associated with the use of vaccinia virus recombinants as vaccines is the existence of a large human population with preexisting immunity to the vector. Here we showed that after a booster with attenuated recombinant modified vaccinia virus Ankara (rMVA), higher humoral and cellular immune responses to foreign antigens (human immunodeficiency virus type 1 Env and β-galactosidase) were found in mice preimmunized with rMVA than in mice primed with the virulent Western Reserve strain and boosted with rMVA. This enhancement correlated with higher levels of expression of foreign antigens after the booster.

scholarly journals Heterologous Prime/Boost Immunization of Rhesus Monkeys by Using Diverse Poxvirus Vectors

2007 ◽  
Vol 81 (16) ◽  
pp. 8563-8570 ◽  
Author(s):  
Sampa Santra ◽  
Yue Sun ◽  
Jenny G. Parvani ◽  
Valerie Philippon ◽  
Michael S. Wyand ◽  
...  
Keyword(s):  
Immune Responses ◽  
Vaccinia Virus ◽  
Rhesus Monkeys ◽  
Recombinant Vaccinia Virus ◽  
Boost Regimen ◽  
Cellular Immune Responses ◽  
Modified Vaccinia Virus Ankara ◽  
Immunodeficiency Virus ◽  
Boost Immunization ◽  
Cellular Immune

ABSTRACT As the diversity of potential immunogens increases within certain classes of vectors, the possibility has arisen of employing heterologous prime/boost immunizations using diverse members of the same family of vectors. The present study was initiated to explore the use of divergent pox vectors in a prime/boost regimen to elicit high-frequency cellular immune responses to human immunodeficiency virus type 1 envelope and simian immunodeficiency virus gag in rhesus monkeys. We demonstrated that monkeys vaccinated with a recombinant modified vaccinia virus Ankara (rMVA) prime/recombinant fowlpox virus (rFPV) boost regimen and monkeys vaccinated with a recombinant vaccinia virus prime/rFPV boost regimen developed comparable cellular immune responses that were greater in magnitude than those elicited by a homologous prime/boost with rMVA. Nevertheless, comparable magnitude recall cellular immune responses were observed in monkeys vaccinated with heterologous and homologous recombinant poxvirus following challenge with the CXCR4-tropic SHIV-89.6P. Consistent with this finding, comparable levels of containment of viral replication and CD4+ T-lymphocyte preservation were seen in these groups of recombinant poxvirus-vaccinated monkeys. This study supports further exploration of combining recombinant vectors of the same family in prime/boost immunization strategies to optimize vaccine-elicited cellular immune responses.

scholarly journals Critical Role for Env as well as Gag-Pol in Control of a Simian-Human Immunodeficiency Virus 89.6P Challenge by a DNA Prime/Recombinant Modified Vaccinia Virus Ankara Vaccine

2002 ◽  
Vol 76 (12) ◽  
pp. 6138-6146 ◽  
Author(s):  
Rama Rao Amara ◽  
James M. Smith ◽  
Silvija I. Staprans ◽  
David C. Montefiori ◽  
Francois Villinger ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Immune Responses ◽  
Vaccinia Virus ◽  
Critical Role ◽  
Viral Control ◽  
Modified Vaccinia Virus Ankara ◽  
Immunodeficiency Virus ◽  
Aids Vaccines ◽  
Induced Apoptosis ◽  
Cellular Immune

ABSTRACT Cellular immune responses against epitopes in conserved Gag and Pol sequences of human immunodeficiency virus type 1 have become popular targets for candidate AIDS vaccines. Recently, we used a simian-human immunodeficiency virus model (SHIV 89.6P) with macaques to demonstrate the control of a pathogenic mucosal challenge by priming with Gag-Pol-Env-expressing DNA and boosting with Gag-Pol-Env-expressing recombinant modified vaccinia virus Ankara (rMVA). Here we tested Gag-Pol DNA priming and Gag-Pol rMVA boosting to evaluate the contribution of anti-Env immune responses to viral control. The Gag-Pol vaccine raised frequencies of Gag-specific T cells similar to those raised by the Gag-Pol-Env vaccine. Following challenge, these rapidly expanded to counter the challenge infection. Despite this, the control of the SHIV 89.6P challenge was delayed and inconsistent in the Gag-Pol-vaccinated group and all of the animals underwent severe and, in most cases, sustained loss of CD4+ cells. Interestingly, most of the CD4+ cells that were lost in the Gag-Pol-vaccinated group were uninfected cells. We suggest that the rapid appearance of binding antibody for Env in Gag-Pol-Env-vaccinated animals helped protect uninfected CD4+ cells from Env-induced apoptosis. Our results highlight the importance of immune responses to Env, as well as to Gag-Pol, in the control of immunodeficiency virus challenges and the protection of CD4+ cells.

scholarly journals Cellular Immune Responses of Schistosomiasis Patients Are Altered by Human Immunodeficiency Virus Type 1 Coinfection

2001 ◽  
Vol 184 (4) ◽  
pp. 488-496 ◽  
Author(s):  
Pauline N. M. Mwinzi ◽  
Diana M. S. Karanja ◽  
Daniel G. Colley ◽  
Alloys S. S. Orago ◽  
W. Evan Secor
Keyword(s):  
Human Immunodeficiency Virus ◽  
Immune Responses ◽  
Human Immunodeficiency Virus Type ◽  
Virus Type ◽  
Cellular Immune Responses ◽  
Immunodeficiency Virus ◽  
Cellular Immune

scholarly journals Human Immunodeficiency Virus Type 1-Hepatitis C Virus Coinfection: Intraindividual Comparison of Cellular Immune Responses against Two Persistent Viruses

2002 ◽  
Vol 76 (6) ◽  
pp. 2817-2826 ◽  
Author(s):  
Georg M. Lauer ◽  
Tam N. Nguyen ◽  
Cheryl L. Day ◽  
Gregory K. Robbins ◽  
Theresa Flynn ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Immune Responses ◽  
T Lymphocyte ◽  
Viral Loads ◽  
Cellular Immune Responses ◽  
Immunodeficiency Virus ◽  
Cellular Immune ◽  
Lymphocyte Responses ◽  
Hiv 1

ABSTRACT Both human immunodeficiency virus type 1 (HIV-1) and hepatitis C virus (HCV) lead to chronic infection in a high percentage of persons, and an expanding epidemic of HIV-1-HCV coinfection has recently been identified. These individuals provide an opportunity for simultaneous assessment of immune responses to two viral infections associated with chronic plasma viremia. In this study we analyzed the breadth and magnitude of the CD8+- and CD4+-T-lymphocyte responses in 22 individuals infected with both HIV-1 and HCV. A CD8+-T-lymphocyte response against HIV-1 was readily detected in all subjects over a broad range of viral loads. In marked contrast, HCV-specific CD8+-T-lymphocyte responses were rarely detected, despite viral loads in plasma that were on average 1,000-fold higher. The few HCV-specific responses that were observed were relatively weak and limited in breadth. CD4-proliferative responses against HIV-1 were detected in about half of the coinfected subjects tested, but no proliferative response against any HCV protein was found in these coinfected persons. These data demonstrate a major discordance in immune responses to two persistent RNA viruses. In addition, they show a consistent and profound impairment in cellular immune responses to HCV compared to HIV-1 in HIV-1-HCV-coinfected persons.

scholarly journals Human Immunodeficiency Virus (HIV)–Specific Cellular Immune Responses in Newborns Exposed to HIV In Utero

2002 ◽  
Vol 34 (2) ◽  
pp. 267-276 ◽  
Author(s):  
Louise Kuhn ◽  
Stephen Meddows‐Taylor ◽  
Glenda Gray ◽  
Caroline Tiemessen
Keyword(s):  
Human Immunodeficiency Virus ◽  
Immune Responses ◽  
In Utero ◽  
Cellular Immune Responses ◽  
Immunodeficiency Virus ◽  
Cellular Immune

scholarly journals Presence of Human Immunodeficiency Virus–1–Specific CD4 and CD8 Cellular Immune Responses in Children with Full or Partial Virus Suppression

2003 ◽  
Vol 188 (6) ◽  
pp. 873-882 ◽  
Author(s):  
Emmanouil Papasavvas ◽  
Johan K. Sandberg ◽  
Richard Rutstein ◽  
Elizabeth C. Moore ◽  
Agnieszka Mackiewicz ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Immune Responses ◽  
Cellular Immune Responses ◽  
Immunodeficiency Virus ◽  
Cellular Immune ◽  
Virus Suppression ◽  
Human Immunodeficiency Virus 1

scholarly journals Induction of Cellular Immune Responses to Simian Immunodeficiency Virus Gag by Two Recombinant Negative-Strand RNA Virus Vectors

2004 ◽  
Vol 78 (17) ◽  
pp. 9366-9375 ◽  
Author(s):  
Yurie Nakaya ◽  
Takaaki Nakaya ◽  
Man-Seong Park ◽  
Jerome Cros ◽  
Jiro Imanishi ◽  
...  
Keyword(s):  
Immune Responses ◽  
Vaccinia Virus ◽  
Simian Immunodeficiency Virus ◽  
Rna Virus ◽  
Influenza Viruses ◽  
Gag Protein ◽  
Virus Vectors ◽  
Cellular Immune Responses ◽  
Immunodeficiency Virus ◽  
Cellular Immune

ABSTRACT A recombinant Newcastle disease virus (rNDV) expressing simian immunodeficiency virus (SIV) Gag protein (rNDV/SIVgag) was generated. The rNDV/SIVgag virus induced Gag-specific cellular immune responses in mice, leading to a specific anti-Gag antiviral immunity. This was evidenced by the inhibition of growth of recombinant vaccinia virus expressing an identical Gag antigen (rVac/SIVgag) but not of wild-type vaccinia virus in rNDV/SIVgag-immunized mice. Among intravenous, intraperitoneal, or intranasal immunization routes, intranasal administration induced the strongest protective response against challenge with rVac/SIVgag. We further demonstrated that these immune responses were greatly enhanced after booster immunization with recombinant influenza viruses expressing immunogenic portions of SIV Gag. The magnitude of the protective immune response correlated with the levels of cellular immune responses to Gag, which were still evident 9 weeks after immunization. These results suggest that rNDV and influenza virus vectors are suitable candidate vaccines against AIDS as well as against other infectious diseases.

Sign in / Sign up

Export Citation Format

Share Document